Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
Fabhalta a few days ago became the first FDA-approved agent for complement 3 glomerulopathy (C3G). Travere has recently filed ...
Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US for IgAN, a disease characterised by the accumulation of antibodies in the ...
IgAN is a progressive, rare kidney disease in which the immune system attacks the kidneys, often causing glomerular inflammation and proteinuria.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback